...
首页> 外文期刊>Applied Organometallic Chemistry >Synthesis, Structural, Biological Evaluation, Molecular Docking and DFT Studies of Co(II), Ni(II), Cu(II), Zn(II), Cd(II) and Hg(II) Complexes bearing Heterocyclic Thiosemicarbazone ligand
【24h】

Synthesis, Structural, Biological Evaluation, Molecular Docking and DFT Studies of Co(II), Ni(II), Cu(II), Zn(II), Cd(II) and Hg(II) Complexes bearing Heterocyclic Thiosemicarbazone ligand

机译:Co(II),Ni(II),Cu(II),Zn(II),CD(II)和HG(II)复合物的合成,结构,生物学评价,分子对接和DFT研究含有杂环硫代吡咯癫痫毒剂配体

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A new ligand, 2-aminonicotinaldehyde N-methyl thiosemicarbazone (ANMTSC) and its metal complexes [Co(II) (1); Ni(II) (2); Cu(II) (3); Zn(II) (4); Cd(II) (5) or Hg(II) (6)] were synthesized. The compounds were characterized by analytical methods and various spectroscopic (infrared, magnetic, thermal, H-1, C-13 NMR, electronic and ESR) tools. The structure of ANMTSC ligand was confirmed by single crystal X-ray diffraction study. The spectral data of metal complexes indicate that the ligand acts as mononegative, bidentate coordination through imine nitrogen (N) and thiocarbonyl sulphur (S-) atoms. The proposed geometries for complexes were octahedral (1-2), distorted octahedral (3) and tetrahedral (4-6). Computational details of theoretical calculations (DFT) of complexes have been discussed. The compounds were subjected to antimicrobial, antioxidant, antidiabetic, anticancer, ROS, studies and EGFR targeting molecular docking analysis. Complex 5 has shown excellent antibacterial activity and the complexes 2 and 5 have shown good antifungal activity. The complexes 1 and 4 displayed good antioxidant property with IC50 values of 11.17 +/- 1.92M and 10.79 +/- 1.85M, respectively compared to standard. In addition, in vitro anticancer activity of the compounds was investigated against HeLa, MCF-7, A549, IMR-32 and HEK 293 cell lines. Among all the compounds, complex 4 was more effective against HeLa (IC50=10.28 +/- 0.69M), MCF-7 (IC50=9.80 +/- 0.83M), A549 (IC50=11.08 +/- 0.57M) and IMR-32 (10.41 +/- 0.60M) exhibited superior anticancer activity [IC50=9.80 +/- 0.83 (4) and 9.91 +/- 0.37M (1)] against MCF-7 compared with other complexes.
机译:一种新的配体,2-氨基丙氨酸醛N-甲基硫代甲基毒(ANMTSC)及其金属配合物[CO(II)(1);倪(ii)(2); CU(ii)(3); Zn(ii)(4);合成CD(II)(5)或Hg(II)(II)]。通过分析方法和各种光谱(红外,磁,热,H-1,C-13 NMR,电子和ESR)工具表征化合物。通过单晶X射线衍射研究证实了ANMTSC配体的结构。金属配合物的光谱数据表明,配体通过亚胺氮(N)和硫代羰基硫(S-)原子作为单一的双齿配位。复合物的拟议几何形状是八面体(1-2),扭曲的八面体(3)和四面体(4-6)。已经讨论了复合物的理论计算(DFT)的计算细节。将化合物进行抗微生物,抗氧化剂,抗糖尿病,抗癌,ROS,研究和EGFR靶向分子对接分析。复合物5显示出优异的抗菌活性,复合物2和5显示出良好的抗真菌活性。复合物1和4显示良好的抗氧化性能,与标准相比,IC50值为11.17 +/- 1.92m和10.79 +/- 1.85米。此外,针对Hela,MCF-7,A549,IMR-32和HEK 293细胞系研究了化合物的体外抗癌活性。在所有化合物中,复合物4对Hela(IC50 = 10.28 +/- 0.69M)更有效,MCF-7(IC50 = 9.80 +/- 0.83M),A549(IC50 = 11.08 +/- 0.57M)和IMR -32(10.41 +/- 0.60m)表现出优越的抗癌活动[IC50 = 9.80 +/- 0.83(4)和9.91 +/- 0.37M(1)]与MCF-7相比,与其他复合物相比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号